Haemonetics to Acquire OpSens for USD 253m.

MANews-(C)2009-2023

Boston-based medical technology company Haemonetics Corp. (NYSE: HAE) has agreed to acquire Canada-based cardiology-focussed medical device company OpSens, Inc. (TSC: OPS) OTCQX; OPSSF) in an all-cash transaction representing a value of approximately USD253 m, the company said.

OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology.

This transaction creates compelling financial and strategic benefits for Haemonetics:

Expands Hospital business unit portfolio with innovative fiber optic sensor technology in the attractive interventional cardiology market.

Leverages Haemonetics' commercial and geographic breadth to accelerate adoption.

Augments long-term growth with additional product and market expansion opportunities.

The transaction will be affected by way of an arrangement under the Business Corp.s...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT